- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe active rheumatoid arthritis
- Meeting Date: March 2016
- Public Summary Document (PSD) March 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2016 PBAC Meeting - Word
Tocilizumab – March 2016
Tocilizumab: 162 mg/0.9 mL injection, 4 x 0.9 mL syringes, Actemra®
Last updated
1 July 2016